Colorectal Cancer Stem Cell Immune Checkpoint Expression Profiles

Ola J. Hussein's 2026 study profiles inhibitory immune checkpoint expression in colorectal cancer stem cells. The analysis integrates experimental data from four cell lines with clinical and RNA-seq data from The Cancer Genome Atlas. It links stemness scores to tumor immunity and immunotherapy biomarker levels.

Use Cases

• Correlate mRNA expression-based stemness index (mRNAsi) with immune cell infiltration levels from TCGA clinical data.
• Analyze associations between stemness scores and immunotherapy biomarkers like tumor mutational burden (TMB) and microsatellite instability (MSI).
• Model the relationship between inhibitory immune checkpoint expression (e.g., PD-L1, B7-H3, CD47) and CSC-enrichment status across cell lines.
• Identify potential CSC-specific immune checkpoint targets for predictive biomarker development.

Strengths

• Integrates experimental cell line data with large-scale clinical genomics data from TCGA.
• Analysis includes multiple validation methods: real-time PCR, Western blotting, immunofluorescence, and flow cytometry.
• Focuses on a clinically relevant subpopulation (cancer stem cells) with clear methodological enrichment.

Limitations

• Dataset is a 5.8 MB document, not a structured data table, limiting direct computational analysis.
• Experimental findings are derived from only four colorectal cancer cell lines, limiting generalizability.
• Clinical correlations are observational and do not establish causal mechanisms.

Provenance

Source

figshare, authored by Ola J. Hussein.

Collection Method

Experimental profiling of CSC-enriched spheroids from cell lines combined with bioinformatics analysis of TCGA-COAD data.

Time Range

null

Freshness

Last updated in April 2026.

Geography

null